Plasma homocysteine levels in patients treated with levodopa: Motor and cognitive associations

Neurological Research

Volumn 28, Issue 8, 2006, Pages 853-858

  Ozer, Feriha ^a   Meral, Hasan ^a   Hanoglu, Lutfu ^b   Aydemir, Tuba ^a   Yilsen, Meral ^a   Cetin, Sibel ^a   Ozturk, Oya ^a   Seval, Hatice ^a   Koldas, Macit ^a  

^a HASEKI EDUCATION AND RESEARCH HOSPITAL   (Turkey)

^b Bakirkoy Neurology Center   (Turkey)

Author keywords

Cognitive functions; Homocysteine; Idiopathic Parkinson's disease; Levodopa

Indexed keywords

CYANOCOBALAMIN; FOLIC ACID; HOMOCYSTEINE; LEVODOPA;

ADULT; AGED; ARTICLE; BLOOD LEVEL; BRAIN FUNCTION; CLINICAL ARTICLE; CLINICAL FEATURE; CLOCK DRAWING TEST; COGNITION; CONTROLLED STUDY; DEMOGRAPHY; DISEASE ASSOCIATION; DOSE RESPONSE; DRUG DOSE INCREASE; FEMALE; FRONTAL CORTEX; HUMAN; HYPERHOMOCYSTEINEMIA; IDIOPATHIC DISEASE; MALE; MEMORY; MENTAL TEST; MOTOR PERFORMANCE; PARKINSON DISEASE; PSYCHOMETRY; RATING SCALE; SHORT TEST OF MENTAL STATUS; UNIFIED PARKINSONS DISEASE RATING SCALE; VITAMIN SUPPLEMENTATION;

AGED; AGED, 80 AND OVER; ANTIPARKINSON AGENTS; CASE-CONTROL STUDIES; COGNITION; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; FOLIC ACID; HOMOCYSTEINE; HUMANS; LEVODOPA; MALE; MIDDLE AGED; MOTOR ACTIVITY; NEUROPSYCHOLOGICAL TESTS; PARKINSON DISEASE; STATISTICS, NONPARAMETRIC; VITAMIN B 12;

EID: 33845407001     PISSN: 01616412     EISSN: None     Source Type: Journal    
DOI: 10.1179/016164106X110445     Document Type: Article

References (27)

1. Clarke R, Smith AD, Jobst KA, et al. Folate, vitamin B12, and serum total homocysteine levels in confirmed Alzheimer disease. Arch Neurol 1998; 55: 1449-1455
2. Seshadri S, Beiser A, Selhub J, et al. Plasma homocysteine as a risk factor for dementia and Alzheimer's disease. N Engl J Med 2002; 346: 476-483
3. Morris MS. Homocysteine and Alzheimer's disease. Lancet Neurol 2003; 2: 425-428.
4. Prins ND, Den Heijer T, Hofman A, et al. Homocysteine and cognitive function in the elderly: The Rotterdam Scan Study. Neurology 2002; 59: 1375-1380
5. Refsum H, Ueland PM, Nygard O, et al. Homocysteine and cardiovascular disease. Annu Rev Med 1998; 49: 31-62
6. Selhub J, Miller JW. The pathogenesis of homocysteinemia: Interruption of the coordinate regulation by S-adenosylmethionine of the remethylation and transsulfuration of homocysteine. Am J Clin Nutr 1992; 55: 131-138
7. Cumming JL. Intellectual impairment in Parkinson's disease: Clinical, pathologic, and biochemical correlates. J Geriatr Psychiatry Neurol 1988; 1: 24-36
8. Allain P, Le Bouil A, Cordillet E, et al. Sulfate and cysteine levels in the plasma of patients with Parkinson's disease. Neurotoxicology 1995; 16: 527-529
9. Muller T, Woitalla D, Hauptmann B, et al. Decrease of methionine and S-adenosylmethionine and increase of homocysteine in treated patients with Parkinson's disease. Neurosci Lett 2001; 308: 54-56
10. Kuhn W, Roebroek R, Blom H, et al. Elevated plasma levels of homocysteine in Parkinson's disease. Eur Neurol 1998; 40: 225-227
11. Kuhn W, Roebroek R, Bloom H, et al. Hyperhomocysteinaemia in Parkinson's disease. J Neurol 1998; 245: 811-812
12. Blandini F, Fancellu R, Martignoni E, et al. Plasma homocysteine and l-dopa metabolism in patients with Parkinson disease. Clin Chem 2001; 47: 1102-1104
13. Miller JW, Selhub J, Nadeau MR, et al. Effect of L-dopa on plasma homocysteine in PD patients: Relationship to B-vitamin status. Neurology 2003; 60: 1125-1129
14. Rogers JD, Sanchez-Saffon A, Frol AB, et al. Elevated plasma homocysteine levels in patients treated with levodopa: Association with vascular disease. Arch Neurol 2003; 60: 59-64
15. Yasui K, Nakaso K, Kowa H, et al. Levodopa-induced hyperhomocysteinaemia in Parkinson's disease. Acta Neurol Scand 2003; 108: 66-67
16. Muller T, Werne B, Fowler B, et al. Nigral endothelial dysfunction, homocysteine, and Parkinson's disease. Lancet 1999; 354: 126-127
17. Postuma RB, Lang AE. Homocysteine and levodopa: Should Parkinson disease patients receive preventative therapy? Neurology 2004; 63: 886-891
18. Fahn S, Elton RL and Members of the UPDRS Development Committee. Unified Parkinson's disease rating scale. In: Fahn S, Marsden CD, Goldstein M, et al. eds. Recent developments in Parkinson's disease II, New York, NY: Macmillan, 1987: pp. 153-163.
19. Kokmen E, Smith GE, Petersen RC, et al. The short test of mental status. Correlations with standardized psychometric testing. Arch Neurol 1991; 48: 725-728
20. Brodaty H, Moore M. The clock drawing test for dementia of Alzheimer's type: A comparison of three scoring methods in a memory disorder clinic. Int J Geriatr Psychiatry 1997; 12: 619-627
21. O. Sozel bellek sürecleri testi (bir ön calisma). Noropsikiyatri arsivi 1992; 29: 196-206
22. Wechsler D, Stone CP. Wechsler Memory Scale, New York, NY: Psychological Corporation, 1945
23. Karakas S, Eski R, Basar E. Türk kültürü için standardizasyonu yapýlmý nöropsikolojik testler topluluou: BÝLNOT Bataryasý. 32. Ulusal Nöroloji Kongresi Kitabý, Istanbul, Turkey: Ufuk Matbaasi, 1997
24. Parker DM, Crawford J. Assessment of frontal lobe dysfunction. In: Crawford J, Parker DM, McKinlay W, eds. A handbook of neuropsychological assesment, Hove, UK: Lawrence Erlbaum Associates, 1992: pp. 267-291
25. Melamed E, Offen D, Shirvan A, et al. Levodopa - an exotoxin or a therapeutic drug? J Neurol 2000; 247 (Suppl. 2): II135-139
26. LeWitt PA, Nyholm D. New developments in levodopa therapy. Neurology 2004; 62: S9-S16
27. O'Suilleabhain PE, Sung V, Hernandez C, et al. Elevated plasma homocysteine level in patients with Parkinson disease: Motor, affective, and cognitive associations. Arch Neurol 2004; 61: 865-868